Partnering

The Pharmaceutical Research and Manufacturers of America (PhRMA), an industry trade group of innovator-research-based pharmaceutical companies, and nine of its member companies and the US National Institutes of Health (NIH)…

Eli Lilly and Company and CureVac, a Tübingen, Germany-headquartered clinical-stage biopharmaceutical company focused on mRNA (messenger ribonucleic acid)-based drug development, have partnered to develop cancer vaccine products in a deal…

Rutgers University and the New Jersey Innovation Institute, a corporation of the New Jersey Institute of Technology, plan to form the New Jersey Continuous Manufacturing Institute (NJCMI) to advance manufacturing…

Bavarian Nordic, a Kvistgaard, Denmark-based biotechnology company, has partnered with SGS, a contract analytical laboratory, to develop a new respiratory syncytial virus (RSV) challenge strain. SGS says the partnership will…

Merck & Co. and Aeglea BioTherapeutics, an Austin, Texas-headquartered biotechnology company, have entered into a clinical collaboration to evaluate the combination of Merck & Co.’s anti-PD-1 therapy, Keytruda (pembrolizumab), with…

Roche and Warp Drive Bio, a Cambridge, Massachusetts-headquartered pharmaceutical company, have partnered to develop antibiotics for drug-resistant bacterial infections in a deal worth up to $300 million. Under the collaboration,…

AbbVie has agreed to license up to three oncolytic viral immunotherapies from Turnstone Biologics, a San Francisco, California-headquartered clinical-stage immuno-oncology company. Turnstone Biologics engineered its oncolytic viral immunotherapy, Maraba, to…

Gilead Sciences has signed a licensing agreement with the Medicines Patent Pool (MPP), a United Nations-backed public health organization, to expand access to its human immunodeficiency virus (HIV) drug, bictegravir…

Merck & Co. has signed a clinical trial and supply agreement with Sellas Life Sciences, a Hamilton, Bermuda-headquartered biopharmaceutical company focused on cancer immunotherapies, to target multiple cancer types. Merck…

Amgen and CytomX Therapeutics, a San Francisco, California-headquartered biopharmaceutical company, have formed a strategic collaboration, worth up to $1.4 billion, to co-develop bispecific antibody constructs for immuno-oncology. Amgen and CytomX…